Skip to main content

Advertisement

SpringerLink
Log in

A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity

  • Original Research
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

Vascular endothelial growth factor (VEGF) promotes the growth of solid tumor mainly via VEGF receptor-1 and receptor-2, which are expressed preferentially in proliferating endothelial cells. Therefore, a strategy for simultaneous blockage of both VEGF receptors may have a useful therapeutic effect in tumor growth. In this study, we utilized a fusion protein which is composed of receptor binding domain of VEGF-A (RBDV) and the constant region fragment (Fc) of a human immunoglobulin G1 (IgG1), to interfere with the growth of human umbilical vein endothelial cells (HUVECs) via VEGF receptors. The results showed that RBDV-IgG1 Fc was able to bind with both VEGF receptor-1 and receptor-2. In addition, RBDV-IgG1 Fc could decrease VEGF-induced proliferation and tube formation among HUVECs. Moreover, the cytotoxic test showed RBDV-IgG1 Fc could also enhance the cytotoxic activity of human natural killing cells. The data are suggesting that the fusion protein, RBDV-IgG1 Fc, may have potential as an angiogenesis antagonist for future tumor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 55:5296–5301

    CAS  Google Scholar 

  • Bae DG, Gho YS, Yoon WH, Chae CB (2000) Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 275:13588–13596

    Article  CAS  Google Scholar 

  • Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G, Mazie JC (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525–1533

    Article  CAS  Google Scholar 

  • Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA (1992) Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med 176:1191–1195

    Article  CAS  Google Scholar 

  • Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P (2004) Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 10:6101–6110

    Article  CAS  Google Scholar 

  • Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  CAS  Google Scholar 

  • Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70

    Article  CAS  Google Scholar 

  • Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313–13316

    Article  CAS  Google Scholar 

  • Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N (1999) VEGF is required for growth and survival in neonatal mice. Development 126:1149–1159

    CAS  Google Scholar 

  • Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8:503–510

    Article  CAS  Google Scholar 

  • Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M (2004) Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10:2253–2264

    Article  CAS  Google Scholar 

  • Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213–223

    Article  CAS  Google Scholar 

  • Hiratsuka S, Kataoka Y, Nakao K, Nakamura K, Morikawa S, Tanaka S, Katsuki M, Maru Y, Shibuya M (2005) Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol Cell Biol 25:355–363

    Article  CAS  Google Scholar 

  • Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398

    Article  CAS  Google Scholar 

  • Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555–557

    Article  CAS  Google Scholar 

  • Ito N, Claesson-Welsh L (1999) Dual effects of heparin on VEGF binding to VEGF receptor-1 and transduction of biological responses. Angiogenesis 3:159–166

    Article  CAS  Google Scholar 

  • Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271:5638–5646

    Article  CAS  Google Scholar 

  • Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249–1256

    Article  CAS  Google Scholar 

  • Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99:1726–1732

    CAS  Google Scholar 

  • Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 94:7192–7197

    Article  CAS  Google Scholar 

  • Plate KH, Breier G, Millauer B, Ullrich A, Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822–5827

    CAS  Google Scholar 

  • Prewett M, Huber J, Li Y, Santiago A, O’Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209–5218

    CAS  Google Scholar 

  • Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N (1998) 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556–20567

    Article  CAS  Google Scholar 

  • Shibusa T, Shijubo N, Abe S (1998) Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4:1483–1487

    CAS  Google Scholar 

  • Smith JK, Mamoon NM, Duhe RJ (2004) Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 14:175–225

    Google Scholar 

  • Tseng FJ, Chen YC, Lin YL, Tsai NM, Lee RP, Chung YS, Chen CH, Liu YK, Huang YS, Hwang CH, Lai YK, Liao KW (2010) A fusion protein with the receptor binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2. Cancer Biol Ther 10:865–873

    Google Scholar 

  • Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988–26995

    CAS  Google Scholar 

  • Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147

    Article  CAS  Google Scholar 

  • Wolff EA, Schreiber GJ, Cosand WL, Raff HV (1993) Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 53:2560–2565

    CAS  Google Scholar 

  • Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765–14770

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the National Science Council, Taipei, Taiwan (NSC97-2313-B-009-002, NSC-97-2320-B-040-005-MY3) and in part by the ATU-MOE project. This study was also supported by National Chiao Tung University (VGHUST94-P5-28) and Hualien Armed Forces Hospital.

Author information

Authors and Affiliations

  1. Department of Orthopedics, Hualien Armed Forces Hospital, Hualien, 97144, Taiwan, ROC

    Feng-Jen Tseng

  2. Graduate Institute of Medical Science, National Defense Medical Center, Taipei, 114, Taiwan, ROC

    Feng-Jen Tseng & Ru-Yu Pan

  3. Institute of Molecular Medicine and Bioengineering, National Chiao Tung University, Hsin-Chu, 30050, Taiwan, ROC

    Yen-Ku Liu, Yu-Ling Lin, Chia-Hung Chen & Yu-Cheng Chen

  4. Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30050, Taiwan, ROC

    Yo-Shong Chung, Wan-Yi Wang & Kuang-Wen Liao

  5. School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, 40203, Taiwan, ROC

    Nu-Man Tsai

  6. Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan, ROC

    Tian-Lu Cheng

  7. Department of Orthopedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan, ROC

    Ru-Yu Pan

  8. Department of Psychiatry, Yuli Veterans Hospital, Hualien, 98142, Taiwan, ROC

    Tsung-Ming Hu

  9. Institute of Nursing and Medical Sciences and Department of Physiology, Tzu Chi University, Hualien, 97004, Taiwan, ROC

    Ru-Ping Lee

Authors
  1. Feng-Jen Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yen-Ku Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yo-Shong Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-Ling Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chia-Hung Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wan-Yi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu-Cheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nu-Man Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tian-Lu Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ru-Yu Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tsung-Ming Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ru-Ping Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kuang-Wen Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kuang-Wen Liao.

Additional information

Feng-Jen Tseng, Yen-Ku Liu, Yo-Shong Chung are the authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tseng, FJ., Liu, YK., Chung, YS. et al. A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity. Cytotechnology 63, 285–293 (2011). https://doi.org/10.1007/s10616-011-9340-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-011-9340-2

Keywords

Search

Navigation